ArticlePathophysiology of haemostasis and thrombosis2010
Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
Article in Pathophysiology of haemostasis and thrombosis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Functional and Regulatory Effects of Factor V Leiden and Factor V rs6028 in Breast Cancer.Genes · 2025Article
- The role of factor V in trauma-induced coagulopathy: an observational and experimental study.Research and practice in thrombosis and haemostasis · 2025Article
- Evaluation of Activated Protein C Resistance Using Thrombin Generation Test.Methods in molecular biology (Clifton, N.J.) · 2023Article
- An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.Blood advances · 2022Article
- Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).Microvascular research · 2021Review
- COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis.Kidney & blood pressure research · 2020Article
- Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.Blood advances · 2017Article
- Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.Pharmaceutical research · 2016Article
- Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.Journal of thrombosis and haemostasis : JTH · 2014Article
- An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.PloS one · 2014Article
- Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy.PloS one · 2014Article
- Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.Thrombosis and haemostasis · 2013Article
- Protein C anticoagulant and cytoprotective pathways.International journal of hematology · 2012Review
- Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation.British journal of haematology · 2011Article
- Continuing education course #2: current understanding of hemostasis.Toxicologic pathology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Coagulation factor V (FV) promotes inactivation of activated factor VIII (FVIIIa) by activated protein C (APC) and protein S. Loss of this APC cofactor activity is proposed to be partially responsible for the APC resistance phenotype of FV(Leiden). However, FVIIIa loses activity rapidly due to dissociation of the A2 domain, and this may be the primary mechanism of FVIIIa inactivation. APC/protein S also readily inactivates activated FV (FVa). We therefore hypothesized that FV can function as an anticoagulant cofactor for APC/protein S in the inactivation of FVa. FV was titrated into FV-deficient plasma, and the APC sensitivity ratio (APCsr; a measure of APC activity) was measured in a clotting assay that was not sensitive to FVIII. Our results showed an increase in APCsr as the FV concentration increased, suggesting an anticoagulant function for FV in this assay. FV(Leiden) showed APC resistance with an APCsr of 1.0. Therefore, under our experimental conditions, FV acted as an anticoagulant cofactor for APC in the inactivation of FVa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.